Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 2Multi-centric Castleman's Disease 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 27Rituximab 26fludarabine phosphate 18Filgrastim 17fludarabine 13Lenalidomide 13Peripheral Blood Stem Cell Transplantation 12Bortezomib 12Bendamustine Hydrochloride 12ibrutinib 9venetoclax 8Etoposide 8Paclitaxel 7Flow Cytometry 7Cyclosporine 7tanespimycin 6aldesleukin 6Prednisone 6Magnetic Resonance Spectroscopy 6Cytarabine 6Biopsy 6obinutuzumab 5Vorinostat 5Tacrolimus 5Radiotherapy 5Polymerase Chain Reaction 5Melphalan 5Gemcitabine 5sargramostim 4belinostat 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell, Marginal Zone × Hyaluronoglucosaminidase × Clear all
NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Thomas Jefferson University

Phase 1 Active not recruiting
4 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡